PDUFA date 13 November 2011 .Partnerdeal for CPI-300 this Q !!!
IGXT has 3.7 M in Cash enuff till 2013 excluding revenue from CPI-300 and upfront payment from new Partnerdeal which is imminent .
PRICE TARGET 3++ DOLLAR
Market Cap : 29 M$ Cash: 3.7 M$ Price : 0,63 $
Shares Out : 45 M ( 20 M shares are held by Insiders + Institutions)
IntelGenx Announces New PDUFA Date for Its Single Dose 450 mg Bupropion Hydrochloride Tablet
Press Release Source: IntelGenx Corp. On Tuesday June 14, 2011, 6:00 am EDT
IntelGenx Corp announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's resubmission of its antidepressant CPI-300 New Drug Application 505(b)(2) in response to the February 2010 Complete Response Letter ("CRL") as a complete, Class 2 response. In addition, the FDA has established November 13, 2011 as its target action date under the Prescription Drug User Fee Act ("PDUFA"). CPI-300 is a novel, high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL®.
Upcoming Milestones • Q3, 2011 Complete licensing agreement for CPI-300 • Q3, 2011 Execute definitive agreement for new development and licensing VersaFilm project • Q3, 2011 Execute definitive agreement for bipolar disorder • Q4, 2011 Obtain FDA approval for CPI-300 • Q4, 2011 Complete pivotal biostudy for anti-migraine VersaFilm